[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588338":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":35,"locations":43,"responsibleParty":64,"collaborators":10,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":10,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":10,"enrollmentInfo":75,"targetDuration":10,"studyType":78,"phases":10,"briefSummary":79,"conditions":80,"keywords":86,"overallStatus":46,"whyStopped":10,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Changchun GeneScience Pharmaceutical Co., Ltd.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Nano-crystalline Megestrol Acetate Oral Suspension +TKI-Based Therapy",null,"Nano-crystalline Megestrol Acetate Oral Suspension, with a specification of 125 mg\u002FmL, the study group takes 5 mL orally per day (625 mg\u002Fday)，TKI Therapy ± chemotherapy \u002F immunotherapy",[13,14],"Drug: Nano-crystalline Megestrol Acetate Oral Suspension","Drug: TKI-Based Therapy",{"label":16,"type":10,"description":17,"interventionNames":18},"TKI-Based Therapy","TKI Therapy ± chemotherapy \u002F immunotherapy",[14],[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"DRUG","Nano-crystalline Megestrol Acetate Oral Suspension","Nano-crystalline Megestrol Acetate Oral Suspension, with a specification of 125 mg\u002FmL, the study group takes 5 mL orally per day (625 mg\u002Fday)",[9],{"type":21,"name":16,"description":16,"armGroupLabels":26,"otherNames":10},[9,16],[28,32],{"name":29,"affiliation":30,"role":31},"Cheng Du","The General Hospital of Northern Theater Command","PRINCIPAL_INVESTIGATOR",{"name":33,"affiliation":34,"role":31},"Zhenguang Du","Organizational Affiliation: Liaoning Cancer Hospital",[36,40],{"name":29,"role":37,"phone":38,"phoneExt":10,"email":39},"CONTACT","024-28851942","dc1115010@sina.com",{"name":33,"role":37,"phone":41,"phoneExt":10,"email":42},"17702485727","d1398@lnph.com",[44,58],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":10},"General Hospital of Northern Theater Command","RECRUITING","Shenyang","Liaoning","110016","China","CN",{"type":53,"coordinates":54},"Point",[55,56],123.43278,41.79222,{"lat":56,"lon":55},{"facility":59,"status":46,"city":47,"state":48,"zip":60,"country":50,"countryCode":51,"cosmosGeoPoint":61,"geoPoint":63,"contacts":10},"Liaoning Cancer Hospital","110042",{"type":53,"coordinates":62},[55,56],{"lat":56,"lon":55},{"type":65,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100588338","real-world-study-on-nano-crystalline-megestrol-acetate-for-cachexia-in-tki-treated-advanced-digestive-tumors-100588338",false,"NCT06940102","Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors","A Multicenter, Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in Patients With Advanced Digestive System Tumors Receiving TKI-Based Therapy","Inclusion Criteria:\n\n* Voluntarily sign a written informed consent (ICF).\n* Age ≥ 18 years at enrollment.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n* Life expectancy ≥ 3 months.\n* Histologically or cytologically confirmed locally advanced or metastatic digestive system tumors that are not amenable to curative treatment, according to the 8th edition TNM staging classification.\n* Not benefiting from local anticancer therapies such as surgery, local ablation, or chemoembolization, and planned to receive TKI-based anticancer treatment, which may be combined with chemotherapy or immunotherapy).\n* Meet the diagnostic criteria for pre-cachexia or cachexia (based on Fearon diagnostic criteria).\n* Good organ function determined\n\nExclusion Criteria:\n\n* Gastrointestinal obstruction.\n* Anorexia due to difficulty in eating caused by neurosis, mental illness, or pain.\n* Comorbidities such as severe cerebrovascular, cardiac, renal, or liver diseases.\n* Major surgery or trauma within the last month.\n* Allergy to any component of the investigational drug.\n* Other conditions deemed unsuitable by the investigator.","ALL","18 Years",{"count":76,"type":77},120,"ESTIMATED","OBSERVATIONAL","This study is a prospective, observational clinical study aimed at evaluating the efficacy of Megestrol Acetate for cachexia in patients with advanced digestive system tumors receiving TKI-based therapy.",[81,82,83,84,85],"Cachexia","Digestive System Cancer","Gastric Cancer","Colorectal Cancer","Hepatocellular Carcinoma",[87,88,89,90,91,92,93,82],"Megestrol Acetate","Nano-crystalline Megestrol Acetate","Targeted Therapy","Tyrosine Kinase Inhibitors","Prospective Studies","Observational Studies","Antineoplastic Agents","2025-04-15",{"date":96,"type":97},"2025-04-23","ACTUAL",{"date":99,"type":97},"2025-03-12",{"date":101,"type":77},"2026-12",{"name":5,"class":6},2]